ArticleMedComm2026
Preclinical Efficacy and Safety Study of a Novel Dermal Fibroblast Modulating Drug, SLI-F06, in Cutaneous Wound Healing.
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Scarring results in significant developmental, functional, aesthetic, and psychological challenges. Despite substantial demand from patients and healthcare providers, no drugs or biologics are currently approved specifically for preventing or reducing scarring. Our previous studies indicate that fibromodulin (FMOD) modulates adult dermal fibroblasts to adopt fetal-like characteristics, thereby improving wound appearance, reducing scar size, and enhancing tensile strength in adult skin healing. To address the high costs, variability, and safety concerns of producing FMOD through mammalian cells, a novel, chemically synthesized FMOD-derived peptide, SLI-F06, has been developed. SLI-F06 retains FMOD's essential properties, such as promoting cell migration, increasing tensile strength, and stimulating antifibrotic effects. Comprehensive animal studies using models such as mice, rats, Yorkshire pigs (the standard for normal human wound healing), and red Duroc pigs (closely mimicking human proliferative and hypertrophic scarring) demonstrate significant improvements in scar appearance, tensile strength tests, and histological outcomes with SLI-F06. Additionally, a formulation buffer has been developed to maintain physiological pH and osmolality, ensuring the stability of SLI-F06 for a suitable duration in clinical settings after removal from refrigeration. SLI-F06 exhibits no genotoxicity or local or systemic toxicity in extensive studies required by the United States Food and Drug Administration for Investigational New Drug applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.